How to Deliver Safe and Effective Adoptive Cell Therapy Products to Clinical Promise, Commercial Scale Manufacturing and Patients
The event brings together leaders from cancer research institutes, patient advocacy groups, early and late-stage investors, pharmas, & biotechs. 300+, 20+ company presentations, 50+% attendees are corporate and financial investors, analysts, bankers and advisors.
Your opportunity to connect with investors and strategic partners, Digital RESI June focuses on early-stage funding for all life science verticals: drugs, devices, diagnostics, digital health.
LSX is an community of senior life science & healthcare decision-makers that develops connections with the capital and partners we need to grow our businesses.
The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the ALS funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
The Congressionally Directed Medical Research Programs (CDMRP) have announced their research funding opportunities for fiscal year 2022. Here’s an overview of the breast cancer research funding opportunities. Learn more about these awards and others in our upcoming webinar, Wednesday, March 30, 2022, 1 PM (Eastern).
BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person re-engagement across the life sciences industry.
The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.
The Longevity Leaders World Congress brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies and commercialisation to target age-related diseases.
President Biden called on Congress to fund the creation of a new agency, a DARPA for Health. Some breakthrough ideas don’t receive sufficient attention because they are too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. The Advanced Research Projects Agency for Health (ARPA-H) aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will not have intramural labs. It will facilitate research directed at solving practical problems. To date, the kinds of non-dilutive funding opportunities which will be available through ARPA-H (grants, contracts, etc.) have not been defined, but we can make intelligent guesses.